Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care

Table 4 SCORE risk at baseline and follow-up

	Patients without diabetes¹ or MetSyn²			Patients with MetSyn²			Patients with diabetes¹
	N	mean	± SD	N	mean	± SD	N	mean	± SD
Total
baseline	225	6.4	6.0	885	7.4	6.7	818	19.8	14.4
8 weeks	139	3.5	3.1	576	4.0	3.5	607	11.2	8.2
Difference ³	138	-2.7*	3.8	568	-3.2*	3.6	590	-8.7*	8.7
Blood pressure alone
baseline	225	6.4	6.0	885	7.4	6.7	818	19.8	14.4
8 weeks	132	6.1	5.6	557	6.8	5.9	589	19.1	13.2
Difference ³	132	-0.4*	1.2	555	-0.7*	1.4	578	-1.4*	3.3
Risk factors alone
baseline	225	6.4	6.0	885	7.4	6.7	818	19.8	14.4
8 weeks	221	3.9	3.4	873	4.5	4.0	789	12.4	8.8
Difference ³	219	-2.6*	3.4	862	-2.9*	3.3	786	-7.6*	7.7

¹ diagnosis assigned by physician; ² defined by the AHA/NHLBI 2004 [17]; ³ difference versus baseline; * p < 0.0001.

ISSN: 1471-2261